Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DarioHealth Corp.DRIO · Entity 7024 | Director | August 12, 2024 | September 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DarioHealth Corp.
Report date August 12, 2024 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,582 |
Reported balance
After 2024-08-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-08-12 · Conversion · Acquired 772 · Balance 33,582 F1: Pursuant to its terms, the Series B Preferred Stock automatically converted into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date. F2: The Reporting Person's 40 shares of Series B-2 Preferred Stock automatically converted into 15,431 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 772 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 33,582 shares of Common Stock immediately following the conversion. |
| Common StockSEC Table I · non-derivative | Direct | 87,582 |
Reported balance
After 2026-09-24 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-24 · Grant · Acquired 54,000 · Balance 87,582 F3: The restricted share award shall vest in eight equal quarterly installments on the last day of each successive calendar quarter after the grant date over a two-year period. |
| Series B-2 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $1,000.00 · Expires 2024-08-04 | Direct | 0 |
Reported balance
After 2024-08-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-08-12 · Conversion · Disposed 40 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 84 |
Reported balance
Holding disclosure · report date 2024-08-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 84 F4: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to its terms, the Series B Preferred Stock automatically converted into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date.
F2: The Reporting Person's 40 shares of Series B-2 Preferred Stock automatically converted into 15,431 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 772 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 33,582 shares of Common Stock immediately following the conversion.
F3: The restricted share award shall vest in eight equal quarterly installments on the last day of each successive calendar quarter after the grant date over a two-year period.
F4: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 28, 2026 20:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 54,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-111349 · tm2626098-7_4seq1.xml · nonDerivative · entry 2 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,582 F3 · date: The restricted share award shall vest in eight equal quarterly installments on the last day of each successive calendar quarter after the grant date over a two-year period. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 20:08 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-090007 · tm2526001-8_4seq1.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,810 F1 · date: The restricted share award shall vest in two equal installments on the last day of each successive annual anniversary after the grant date over a two-year period. F2 · balance_after: The number of shares beneficially owned reflects the 20-for-1 reverse stock split effected on August 28, 2025. Read SEC document |
| August 12, 2024 Filed Sep 28, 2026 20:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | ConversionSeries B-2 Preferred Stock · Derivative | 40 | $1,000.00 Strike: $1,000.00 | $40,000.00 |
DisclosureSEC source: 0001104659-26-111349 · tm2626098-7_4seq1.xml · derivative · entry 4 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 772 shares Expires 2024-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2024 Filed Sep 28, 2026 20:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | ConversionCommon Stock | 772 | $19.10 | $14,745.20 |
DisclosureSEC source: 0001104659-26-111349 · tm2626098-7_4seq1.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Pursuant to its terms, the Series B Preferred Stock automatically converted into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date. F2 · shares: The Reporting Person's 40 shares of Series B-2 Preferred Stock automatically converted into 15,431 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 772 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 33,582 shares of Common Stock immediately following the conversion. F2 · price: The Reporting Person's 40 shares of Series B-2 Preferred Stock automatically converted into 15,431 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 772 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 33,582 shares of Common Stock immediately following the conversion. F2 · balance_after: The Reporting Person's 40 shares of Series B-2 Preferred Stock automatically converted into 15,431 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 772 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 33,582 shares of Common Stock immediately following the conversion. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:23 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-032414 · tm248350-8_4seq1.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,193 F1 · date: The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in quarterly instalments on the last day of each calendar quarter commencing March 31, 2024 for a two year period. Read SEC document |
| May 04, 2023 Filed May 8, 2023 20:12 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseSeries B-2 Preferred Stock · Derivative | 40 | $1,000.00 Strike: $3.37 | $40,000.00 |
DisclosureSEC source: 0001104659-23-057159 · tm2315002-3_4seq1.xml · derivative · entry 3 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40 Underlying: Common Stock · Not disclosed shares Expires 2026-05-04 F2 · derivative.expiration_date: The Series B Preferred Stock will automatically convert into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date. F3 · derivative.underlying_shares: The Series B Preferred Stock initially converts into shares of common stock at a conversion price of $3.37. In addition, the holders of Series B Preferred Stock will also be entitled dividends payable as follows: (i) a number of shares of Common Stock equal to five percent (5.0%) of the number of shares of Common Stock issuable upon conversion of the Series B Preferred Stock then held by such holder for each full quarter anniversary of holding for a total of four (4) quarters from the closing date, and (ii) a number of shares of common stock equal to ten percent (10%) of the number of shares of common stock issuable upon conversion of the Series B Preferred Stock then held by such holder on the fifth full quarter from the closing date. Read SEC document |
| May 18, 2022 Filed May 20, 2022 21:04 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-063456 · tm2216123-9_4seq1.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,193 F1 · date: The shares vest over three years as follows: 8.333% shall vest after 3 months from the grant date, and the remaining shares vest in 11 equal instalments every 3 months thereafter. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:09 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantRestricted Stock Grant | 16,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-006303 · tm213677-10_4seq1.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,193 F1 · date: The shares vest over three years as follows: 8.333% shall vest on March 31, 2021, and the remaining shares vest in 11 equal instalments every 3 months thereafter. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 20:08 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 2,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-085622 · tm2025176d2_4.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,584 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the second quarter of 2020. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 500 | $6.50 | $3,250.00 |
DisclosureSEC source: 0001104659-20-072006 · tm2022329-1_4.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,206 Read SEC document |
| June 09, 2020 Filed Jun 9, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 1,000 | $5.96 | $5,960.00 |
DisclosureSEC source: 0001104659-20-071372 · tm2022153d3_4.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,706 Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 20:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 2,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-044152 · tm2015091d3_4.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,706 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the first quarter of 2020. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:15 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-021773 · tm207834-7_4.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,328 Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 21:07 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 2,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-008682 · tm206156d1_4.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,328 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the fourth quarter of 2019. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 21:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 2,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-076114 · tm1927375-1_4.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,950 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the third quarter of 2019 in the aggregate amount of $10,250. Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 11:49 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 12,888 | $0.45 | $5,741.60 |
DisclosureSEC source: 0001144204-19-040499 · tv527906_4.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,443 F1 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.444 to $0.449, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). Read SEC document |
| July 09, 2019 Filed Jul 10, 2019 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 34,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-034298 · tv524961_4.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,555 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the first and second quarters of 2019 in the aggregate amount of $20,500. Read SEC document |
| April 29, 2019 Filed Apr 30, 2019 21:01 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 300,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-022454 · tv520219_4.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,389 Read SEC document |
| January 27, 2019 Filed Jan 29, 2019 21:03 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 10,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-003521 · tv511875_4.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,632 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the fourth quarter of 2018 in the amount of $10,250. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 21:01 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 1,500 | $0.94 | $1,410.00 |
DisclosureSEC source: 0001144204-18-061507 · tv507826_4.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,382 Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 21:02 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 1,300 | $0.77 | $1,001.00 |
DisclosureSEC source: 0001144204-18-061229 · tv507711_4.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,882 Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 20:23 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 10,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-052755 · tv504219_form4.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,582 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the third quarter of 2018 in the amount of $10,250. Read SEC document |
| September 13, 2018 Filed Sep 26, 2018 20:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseWarrant to purchase Common Stock · Derivative | 26,669 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001144204-18-050922 · tv503566_form4.xml · derivative · entry 4 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 26,669 Underlying: Common Stock · 26,669 shares Expires 2019-08-28 F1 · shares: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F3 · price: The Warrants were issued in connection with the purchase of the Common Stock and the Series D Convertible Preferred Stock reported herein. F1 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 13, 2018 Filed Sep 26, 2018 20:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseSeries D Convertible Preferred Stock · Derivative | 5,240 | $3.60 Strike: $0.90 | $18,864.00 |
DisclosureSEC source: 0001144204-18-050922 · tv503566_form4.xml · derivative · entry 3 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 5,240 Underlying: Common Stock · 20,960 shares Expires not disclosed F1 · shares: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F2 · derivative.exercise_date: The Series D Convertible Preferred Stock automatically converts into Common Stock on a 1:4 basis upon shareholder approval of the conversion and has no expiration date. F2 · derivative.expiration_date: The Series D Convertible Preferred Stock automatically converts into Common Stock on a 1:4 basis upon shareholder approval of the conversion and has no expiration date. F1 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 13, 2018 Filed Sep 26, 2018 20:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 12,376 | $0.90 | $11,138.40 |
DisclosureSEC source: 0001144204-18-050922 · tv503566_form4.xml · nonDerivative · entry 1 Shaked Yoav · CIK 0001744499 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 12,376 F1 · shares: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F1 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.